Natco Pharma submits application with USFDA for generic cancer drug
Natco Pharma on Monday said it has submitted a new application with the US health regulator for marketing authorisation of the generic version of Olaparib tablets, used in treating certain forms of ovarian, breast, pancreatic and prostate cancers, via an exchange filing. The company has submitted an Abbreviated New Drug Application (ANDA) containing a 'paragraph IV'
New Jersey United States Astrazeneca Olaparib Natco Pharma Alembic Pharmaceuticals Drug Administration
Source: freepressjournal.in